Biopharma news, November 5, 2026
The most important drug and company news of November 5, 2026, ranked, each linked to its Gosset profiles.
Pivotal readout
Orelabrutinib hits primary goal in Chinese phase 3 study in chronic ITP
InnoCare Pharma said its BTK inhibitor orelabrutinib beat placebo in a 196-patient phase 3 trial in adults with previously treated chronic immune thrombocytopenia. Durable platelet response reached 32.8%, a 25.5-point gain over placebo (P=0.0001), and safety resembled placebo. The data will be an oral talk at ASH; a Chinese filing for this use was accepted in May.
Source types: News article. Sources are available to Gosset users. Log in to see them.
Licensing & partnership
Qyuns licenses a second TL1A bispecific to Caldera, this time paired with IL-17
Qyuns Therapeutics granted Caldera Therapeutics exclusive global rights to a preclinical antibody that hits TL1A together with IL-17A and IL-17A/F, in a deal valued at up to $780 million. It is the second licence between the two companies, after their 2025 agreement on QX030N, an IL-23p19 by TL1A bispecific aimed at inflammatory bowel disease.
Source types: SEC/exchange filing · News article. Sources are available to Gosset users. Log in to see them.
Approval
China clears Immunochina's CD19 CAR-T IM19 for relapsed large B-cell lymphoma
The NMPA approved IM19, an autologous CD19-directed CAR-T from Immunochina Pharmaceuticals, for adult large B-cell lymphoma that has relapsed or resisted two or more earlier systemic lines. It is the company's first marketed product. In the 96-patient confirmatory efficacy set, the three-month response rate was 58.3% and median progression-free survival was 5.98 months.
Source types: News article. Sources are available to Gosset users. Log in to see them.
M&A
ANI Pharmaceuticals bids about $560M for rare disease drugmaker Egetis
ANI Pharmaceuticals made a recommended cash offer for Egetis Therapeutics at SEK 11.25 a share, valued near $560 million. Egetis sells EMCITATE for MCT8 deficiency, which ANI expects could top $300 million in peak annual sales. Holders of about 42% of shares back the deal, which needs 90% acceptance and regulatory clearance.
Source types: Press release. Sources are available to Gosset users. Log in to see them.
Pivotal readout
CBT-001 eye drop meets both primary goals in phase 3 pterygium study
Grand Pharmaceutical Group and Cloudbreak Pharma reported that both doses of CBT-001, a reformulated nintedanib emulsion, beat placebo on eye redness after three months and on lesion length after a year (p<0.001) in a 659-patient international trial. Further analyses continue. If approved, it would be the first medicine for pterygium, which is now managed mainly with surgery.
- DrugCBT-001
- CompanyGrand Pharmaceutical Group
- CompanyCloudbreak Pharma
- TargetCarbonic anhydrase IX
- TrialNCT05456425
Source types: Press release · SEC/exchange filing. Sources are available to Gosset users. Log in to see them.
Licensing & partnership
Boehringer pays $358M upfront for options on six Sino Biopharm cancer biologics
Boehringer Ingelheim signed an option and licence pact with Sino Biopharmaceutical Limited covering six preclinical biologics, five originating at LaNova Medicines. Upfront and near-term payments total $358 million, with as much as $7 billion more in option and milestone fees plus tiered double-digit royalties. Sino Biopharm will run development through global phase 1 before Boehringer decides on each option.
Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.
Approval
Bio-Thera gets China's first golimumab biosimilar approval
China's drug regulator cleared Bio-Thera Solutions' golimumab biosimilar to treat rheumatoid arthritis plus ankylosing spondylitis, the first such copy approved in the country. The same molecule won European approval in February and US approval in May. It is the seventh product, and sixth biosimilar, the company has brought to the Chinese market.
Source types: News article. Sources are available to Gosset users. Log in to see them.
Approval
China clears Yiling's pediatric cold granules, a class 1 traditional Chinese medicine
Chinese regulators approved Yiling Pharmaceutical's Xiaoer Lianhua Ganmao granules for children aged 4 to 12 with common cold of the wind-heat type. The product is a new class 1 traditional Chinese medicine. Yiling also has other candidates in clinical testing and under marketing review.
Source types: News article. Sources are available to Gosset users. Log in to see them.
Pivotal readout
Sinovent's funobactam combination matches relebactam regimen in hospital pneumonia
A phase 3 double-blind trial of Sinovent's imipenem-cilastatin-funobactam in hospital-acquired and ventilator-associated bacterial pneumonia has been published in a leading infectious disease journal. The combination was non-inferior to imipenem-cilastatin-relebactam on 14-day all-cause mortality, with good tolerability. Sinovent positions it as a domestic option against carbapenem-resistant Gram-negative bacteria.
- Drugimipenem
- Drugcilastatin
- CompanySinovent
- TargetPenicillin-binding protein 1A
- TargetPenicillin-binding protein 1B
Source types: Press release. Sources are available to Gosset users. Log in to see them.
Licensing & partnership
Emergent wins up to $22.3M US military order for BioThrax anthrax vaccine
Emergent BioSolutions had an option exercised under an existing indefinite-quantity contract, worth as much as $22.3 million, covering BioThrax deliveries to the US Department of War. The first shipment, valued near $7.4 million, starts this year and the rest follows in 2027. The vaccine is used across the military as pre-exposure protection against anthrax.
Source types: Press release. Sources are available to Gosset users. Log in to see them.